To include your compound in the COVID-19 Resource Center, submit it here.

Going big in Europe

Why Arch's Carrick investment is the opposite of how it usually forms newcos

Arch Venture's biggest investment to date in Europe is also the complete opposite of how the firm normally starts biotech companies. Arch is co-leading a tranched $95 million series A round for Carrick Therapeutics Ltd. with the

Read the full 379 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers